JUNS
JUPITER NEUROSCIENCES, INC.
NASDAQ · Healthcare · Biotechnology · US
$2.86
−4.98%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -64.7%
- EBIT
- -70.5%
- EPS
- —
- Free cash flow
- -28.8%
- Operating cash flow
- -28.8%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- +134.0%
- EPS
- +107.8%
Three-year CAGR
- Revenue
- -54.6%
- EBITDA
- —
- EBIT
- —
- Net income
- —
- EPS
- —
- Free cash flow
- -38.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026